We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against other ...

The challenge of the obesity epidemic is widespread and one that even pediatricians face constantly,” a Connecticut doctor ...

CAMBRIDGE, Mass., February 27, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...

Operator: Good morning and welcome to Scholar Rock’s Fourth Quarter Financial Results and Business Update Call. All ...

Scholar Rock has a 52 week low of $6.76 and a 52 week high of $46.98. The firm has a 50 day simple moving average of $41.89 and a 200 day simple moving average of $28.17. Get Scholar Rock alerts: ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...

CAMBRIDGE, Mass., February 27, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Principal Financial Group Inc. bought a new stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with ...

Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...